Oral Anti-Diabetic Drug Market

ID: MRFR/HC/40608-HCR
200 Pages
Rahul Gotadki
Last Updated: April 24, 2026
Oral Anti-Diabetic Drug Market Research Report By Drug Class (Biguanides, Sulfonylureas, Thiazolidinediones, DPP-4 Inhibitors, SGLT2 Inhibitors), By Action Mechanism (Insulin Sensitizers, Insulin Secretagogues, Alpha-Glucosidase Inhibitors, Renal Glucose Reabsorption Inhibitors), By Prescription Type (Generic, Branded), By Patient Type (Type 1 Diabetes, Type 2 Diabetes, Prediabetes) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Oral Anti-Diabetic Drug Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)2.9%
2024 Market Size$ 109.6 Billion
2025 Market Size$ 112.78 Billion
2035 Market Size$ 150.1 Billion
Key Players
Novo Nordisk
Sanofi
Boehringer Ingelheim
Merck & Co.
AstraZeneca
Johnson & Johnson
Trends
  • Rise of Personalized Medicine
  • Technological Advancements in Drug Delivery
  • Focus on Combination Therapies
Opportunities
  • Rising Healthcare Expenditure
  • Growing Awareness and Education
  • Regulatory Support and Approvals
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Drug Class (USD Billion) | |
      1. 4.1.1 Biguanides | |
      2. 4.1.2 Sulfonylureas | |
      3. 4.1.3 Thiazolidinediones | |
      4. 4.1.4 DPP-4 Inhibitors | |
      5. 4.1.5 SGLT2 Inhibitors |
    2. 4.2 Healthcare, BY Action Mechanism (USD Billion) | |
      1. 4.2.1 Insulin Sensitizers | |
      2. 4.2.2 Insulin Secretagogues | |
      3. 4.2.3 Alpha-Glucosidase Inhibitors | |
      4. 4.2.4 Renal Glucose Reabsorption Inhibitors |
    3. 4.3 Healthcare, BY Prescription Type (USD Billion) | |
      1. 4.3.1 Generic | |
      2. 4.3.2 Branded |
    4. 4.4 Healthcare, BY Patient Type (USD Billion) | |
      1. 4.4.1 Type 1 Diabetes | |
      2. 4.4.2 Type 2 Diabetes | |
      3. 4.4.3 Prediabetes |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Novo Nordisk (DK) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Sanofi (FR) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Boehringer Ingelheim (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Merck & Co. (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 AstraZeneca (GB) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Johnson & Johnson (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Eli Lilly and Company (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 GlaxoSmithKline (GB) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Takeda Pharmaceutical Company (JP) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DRUG CLASS |
    7. 6.4 US MARKET ANALYSIS BY ACTION MECHANISM |
    8. 6.5 US MARKET ANALYSIS BY PRESCRIPTION TYPE |
    9. 6.6 US MARKET ANALYSIS BY PATIENT TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY DRUG CLASS |
    11. 6.8 CANADA MARKET ANALYSIS BY ACTION MECHANISM |
    12. 6.9 CANADA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    13. 6.10 CANADA MARKET ANALYSIS BY PATIENT TYPE |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY DRUG CLASS |
    16. 6.13 GERMANY MARKET ANALYSIS BY ACTION MECHANISM |
    17. 6.14 GERMANY MARKET ANALYSIS BY PRESCRIPTION TYPE |
    18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT TYPE |
    19. 6.16 UK MARKET ANALYSIS BY DRUG CLASS |
    20. 6.17 UK MARKET ANALYSIS BY ACTION MECHANISM |
    21. 6.18 UK MARKET ANALYSIS BY PRESCRIPTION TYPE |
    22. 6.19 UK MARKET ANALYSIS BY PATIENT TYPE |
    23. 6.20 FRANCE MARKET ANALYSIS BY DRUG CLASS |
    24. 6.21 FRANCE MARKET ANALYSIS BY ACTION MECHANISM |
    25. 6.22 FRANCE MARKET ANALYSIS BY PRESCRIPTION TYPE |
    26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT TYPE |
    27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
    28. 6.25 RUSSIA MARKET ANALYSIS BY ACTION MECHANISM |
    29. 6.26 RUSSIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT TYPE |
    31. 6.28 ITALY MARKET ANALYSIS BY DRUG CLASS |
    32. 6.29 ITALY MARKET ANALYSIS BY ACTION MECHANISM |
    33. 6.30 ITALY MARKET ANALYSIS BY PRESCRIPTION TYPE |
    34. 6.31 ITALY MARKET ANALYSIS BY PATIENT TYPE |
    35. 6.32 SPAIN MARKET ANALYSIS BY DRUG CLASS |
    36. 6.33 SPAIN MARKET ANALYSIS BY ACTION MECHANISM |
    37. 6.34 SPAIN MARKET ANALYSIS BY PRESCRIPTION TYPE |
    38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT TYPE |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ACTION MECHANISM |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY PRESCRIPTION TYPE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY DRUG CLASS |
    45. 6.42 CHINA MARKET ANALYSIS BY ACTION MECHANISM |
    46. 6.43 CHINA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    47. 6.44 CHINA MARKET ANALYSIS BY PATIENT TYPE |
    48. 6.45 INDIA MARKET ANALYSIS BY DRUG CLASS |
    49. 6.46 INDIA MARKET ANALYSIS BY ACTION MECHANISM |
    50. 6.47 INDIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    51. 6.48 INDIA MARKET ANALYSIS BY PATIENT TYPE |
    52. 6.49 JAPAN MARKET ANALYSIS BY DRUG CLASS |
    53. 6.50 JAPAN MARKET ANALYSIS BY ACTION MECHANISM |
    54. 6.51 JAPAN MARKET ANALYSIS BY PRESCRIPTION TYPE |
    55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT TYPE |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ACTION MECHANISM |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY ACTION MECHANISM |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE |
    64. 6.61 THAILAND MARKET ANALYSIS BY DRUG CLASS |
    65. 6.62 THAILAND MARKET ANALYSIS BY ACTION MECHANISM |
    66. 6.63 THAILAND MARKET ANALYSIS BY PRESCRIPTION TYPE |
    67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT TYPE |
    68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
    69. 6.66 INDONESIA MARKET ANALYSIS BY ACTION MECHANISM |
    70. 6.67 INDONESIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT TYPE |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY ACTION MECHANISM |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY PRESCRIPTION TYPE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
    78. 6.75 BRAZIL MARKET ANALYSIS BY ACTION MECHANISM |
    79. 6.76 BRAZIL MARKET ANALYSIS BY PRESCRIPTION TYPE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT TYPE |
    81. 6.78 MEXICO MARKET ANALYSIS BY DRUG CLASS |
    82. 6.79 MEXICO MARKET ANALYSIS BY ACTION MECHANISM |
    83. 6.80 MEXICO MARKET ANALYSIS BY PRESCRIPTION TYPE |
    84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT TYPE |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY ACTION MECHANISM |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ACTION MECHANISM |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ACTION MECHANISM |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PRESCRIPTION TYPE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ACTION MECHANISM |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY ACTION MECHANISM |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY ACTION MECHANISM, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY ACTION MECHANISM, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Oral Anti-Diabetic Drug Market Segmentation

Oral Anti-Diabetic Drug Market By Drug Class (USD Billion, 2025-2035)

  • Biguanides
  • Sulfonylureas
  • Thiazolidinediones
  • DPP-4 Inhibitors
  • SGLT2 Inhibitors

Oral Anti-Diabetic Drug Market By Action Mechanism (USD Billion, 2025-2035)

  • Insulin Sensitizers
  • Insulin Secretagogues
  • Alpha-Glucosidase Inhibitors
  • Renal Glucose Reabsorption Inhibitors

Oral Anti-Diabetic Drug Market By Prescription Type (USD Billion, 2025-2035)

  • Generic
  • Branded

Oral Anti-Diabetic Drug Market By Patient Type (USD Billion, 2025-2035)

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Prediabetes

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.